Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs and glucocorticoids

被引:0
|
作者
Koh, Eun-Mi [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
来源
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | 2010年 / 53卷 / 10期
关键词
Rheumatoid arthritis; NSAIDs; DMARDs; Glucocorticoids; RECOMMENDATIONS; MANAGEMENT;
D O I
10.5124/jkma.2010.53.10.871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The medical treatment of rheumatoid arthritis has been dramatically improved with the advances of newer disease-modifying antirheumatic drugs (DMARDs) and biologic agents during previous decades. To prevent joint damage, it is essential to start DMARD treatment early, especially within the first 3 months after diagnosis. Tight control of disease activity, and the thorough monitoring of the treatment's efficacy and the side effects of medications are also important. Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to control pain and swelling of the joints. However, these drugs cannot alter the disease course of rheumatoid arthritis. It is therefore necessary to introduce DMARDs at the beginning of treatment, and, after achieving the effect of DMARDs, NSAIDs should be tapered as soon as possible. The main treatment should be DMARDs, which must be used wisely and appropriately. It is also important to adjust DMARD therapy during the course of treatment according to disease activity. Glucocorticoids have potent anti-inflammatory effects and can control inflammation dramatically. However, because of the diverse and serious side effects of glucocorticoids, the usage of glucocorticoids should be limited to low-dose oral therapy or intra-articular injection, unless otherwise indicated. Along with biologics, there are now various weapons available against rheumatoid arthritis, and it can be treated much more effectively than before.
引用
收藏
页码:871 / 879
页数:9
相关论文
共 50 条
  • [31] Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis
    Wailoo, Allan
    Alava, Monica Hernandez
    Scott, Ian C.
    Ibrahim, Fowzia
    Scott, David L.
    RHEUMATOLOGY, 2014, 53 (10) : 1773 - 1777
  • [32] Nonsteroidal Anti-inflammatory Drugs for Treatment of Acute Gout
    van Durme, Caroline M. P. G.
    Wechalekar, Mihir D.
    Landewe, Robert B. M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (22): : 2276 - 2277
  • [33] Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis
    Balmaceda, Casilda M.
    BMC MUSCULOSKELETAL DISORDERS, 2014, 15
  • [34] PARTICULARITIES OF TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Schiotis, Ruxandra Elena
    Gosa, Dana
    Bocsan, Corina
    Suciu, Soimita
    Buzoianu, Anca Dana
    FARMACIA, 2017, 65 (03) : 479 - 484
  • [35] Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung C.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [36] Pivotal factors for successful withdrawal of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients in remission or with low-disease activity
    Dong Jin Go
    Kichul Shin
    Han Joo Baek
    Seong Wook Kang
    Young Mo Kang
    Jae Bum Jun
    Yun Jong Lee
    Sung Hwan Park
    Yeong Wook Song
    Clinical Rheumatology, 2018, 37 : 307 - 314
  • [37] A review of nonsteroidal anti-inflammatory drugs
    Schellack, Natalie
    Schellack, Gustav
    Fourie, Johani
    SA PHARMACEUTICAL JOURNAL, 2015, 82 (03) : 8 - 18
  • [38] Nonsteroidal Anti-inflammatory Drugs in Ophthalmology
    Kim, Stephen J.
    Flach, Allan J.
    Jampol, Lee M.
    SURVEY OF OPHTHALMOLOGY, 2010, 55 (02) : 108 - 133
  • [39] Pharmacogenetics of nonsteroidal anti-inflammatory drugs
    J E Wyatt
    W L Pettit
    S Harirforoosh
    The Pharmacogenomics Journal, 2012, 12 : 462 - 467
  • [40] Adherence to synthetic disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study
    Juan Mas, Antonio
    Castaneda, Santos
    Cantero Santamaria, Jose, I
    Baquero, Jose L.
    del Toro Santos, Francisco J.
    de Miguel, Alegre
    Castaneda Sanz, Cayetano
    Castano Sanchez, Santos
    Chamizo Carmona, Manuel
    de Toro Santos, Eugenio
    Garcia Aparicio, Francisco Javier
    Garcia Fernandez, Angel Angel
    Garmendia Sanchez, Maria Edilia
    Hernandez Miguel, Elena
    Hidalgo Calleja, Maria Victoria
    Juan Mas, Cristina
    Martinez Lopez, Antonio
    Martinez Taboada, Juan Antonio
    Monteagudo Saez, Victor
    Naranjo Hernandez, Indalecio
    One Martinez, Antonio
    Perez Galan, Javier
    Rodriguez Escalera, Maria Jose
    Gomez de Salazar, Jose Carlos Rosas
    REUMATOLOGIA CLINICA, 2019, 15 (05): : 264 - 270